Loading clinical trials...
Loading clinical trials...
Adjuvant Radiotherapy Combined With Sintilimab Versus Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma With Narrow Margins and High-Risk Features Following Resection: A Multi-center Phase III Randomized Controlled Trial
Conditions
Interventions
Sintilimab
radiotherapy
+1 more
Locations
1
China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, China
Start Date
July 10, 2025
Primary Completion Date
July 9, 2027
Completion Date
November 30, 2028
Last Updated
September 22, 2025
NCT07302074
NCT07493044
NCT07176650
NCT07469319
NCT06951646
NCT07291076
Lead Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions